ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1645	National Cancer Institute	Html	en	Gonzalez Regimen (PDQ®)–Patient Version	Expert-reviewed information summary about the Gonzalez regimen as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	metabolic type 0.635617 cancer prevention 0.611486 NCI Best Case 0.598906 mainstream medical community 0.586423 scientific methods 0.589903 PDQ cancer information 0.678785 Cancer Complementary 0.593506 pancreatic cancer 0.652631 CAM therapies 0.667976 treatment clinical trials 0.608837 National Cancer Institute 0.779385 clinical trials 0.720584 important body processes 0.609904 alternative medicine 0.70039 NIH National Library 0.589764 cancer information summary 0.665644 alternative cancer therapies 0.639162 advanced pancreatic cancer 0.627348 clinical trial 0.631473 National Center 0.597871 PubMed bibliographic database 0.587523 new treatment 0.61493 breast cancer prevention 0.609001 certain scientific questions 0.59076	patients 0.729305 cancer patients 0.591541 7-year clinical study 0.608255 latest published information 0.596234 Gonzalez regimen 0.972553 easy-to-use search tool 0.586572 Integrative Health 0.595025 NCI PDQ cancer 0.643516 cancer information database 0.621215 Health care professionals 0.588662 alternative therapies 0.621194 purely alternative approaches 0.593886 complementary therapies 0.587662 Gonzalez regimen group 0.693146 New York physician 0.598832 health professional versions 0.595534 prospective studies 0.59024 cancer 0.820591 research studies 0.596285 Nicholas Gonzalez 0.593123 conventional treatments 0.632214 Dr. Gonzalez 0.59152 small number 0.597616	CLICK HERE
1672	National Cancer Institute	Html	en	Pediatric Supportive Care (PDQ®)–Patient Version	Expert-reviewed information summary about the unique issues that arise for children during their treatment for cancer, after the completion of treatment, and as adult survivors of cancer.	cancer treatment 0.673763 mental health 0.594918 childhood cancer survivors 0.660763 PDQ cancer information 0.632459 health care team 0.597981 childhood cancer patients 0.499693 children 0.602725 cancer treatment doctors 0.562323 different age groups 0.509717 clinical trials 0.536936 mental health problems 0.576551 early treatment 0.493575 cancer information summary 0.576245 regular mental health 0.520572 NCI PDQ cancer 0.534007 effects 0.524597 supportive care 0.660168 young adults 0.515271 childhood cancer 0.678101 late effects 0.509447 health care support 0.494832 care 0.735246 child 0.686462 end-of-life care 0.567481 parents 0.506649	cancer treatments 0.501032 treatment 0.871904 mental health specialist 0.520368 cancer experience 0.49362 mental health check-ups 0.521913 palliative care 0.553378 Cancer Information Service 0.502777 Follow-up cancer care 0.566023 child end-of-life care 0.503834 National Cancer Institute 0.574409 certain childhood cancer 0.500961 health care 0.604883 Palliative Care Editorial 0.521086 cancer treatment doctor 0.57306 new treatment 0.522928 Cancer Care page 0.512127 Care Editorial Board 0.522941 PDQ summary 0.567319 cancer information summaries 0.506731 cancer patient 0.507833 comprehensive cancer information 0.506663 PDQ Supportive Care 0.533813 cancer 0.997123 follow-up care 0.516276	CLICK HERE
1689	National Cancer Institute	Html	en	Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood central nervous system germ cell tumors.	craniospinal irradiation 0.568926 intracranial germinoma 0.542559 survival rates 0.505415 excellent survival rates 0.497286 endodermal sinus tumor 0.492396 germ cell tumor 0.543477 chemotherapy 0.510034 reduced-volume radiation therapy 0.492394 ifosfamide based chemotherapy 0.484152 Tumors Treatment Overview 0.506029 primordial germ cells 0.489907 focal radiation therapy 0.518434 pure germinomas 0.484971 Radiat Oncol Biol 0.492523 tumor markers 0.56413 radiation therapy doses 0.490668 CNS germ cell 0.55586 tumor markers AFP 0.505621 cerebrospinal tumor markers. 0.502663 conventional whole-brain irradiation 0.482504 whole-ventricular radiation therapy 0.492409 CSF AFP levels 0.509387 nongerminomatous germ cell 0.513106 cell tumor study 0.490435 yolk sac tumor 0.491117	germ cell theory 0.506108 common solid tumor 0.502347 germinomatous germ cell 0.4915 primary chemotherapy 0.487412 radiation therapy 0.751812 et al. 0.485468 Low-dose craniospinal irradiation 0.484891 CNS GCTs 0.523584 whole-ventricle radiation therapy 0.491449 SIOP CNS GCT 0.490345 brain tumor treatment 0.516207 primary brain tumors 0.544753 neoadjuvant chemotherapy results 0.491554 Pediatr Blood Cancer 0.568832 response-based radiation therapy 0.486149 radiation treatment volume 0.488339 boost radiation therapy 0.486976 nervous system tumors 0.483298 Brain Tumor Study 0.49693 Oncol Biol Phys 0.49429 specific chemotherapy regimen 0.484857 intracranial germ cell 0.58985 germ cell tumors 0.911962 radiation therapy fields 0.485192	CLICK HERE
1912	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles.	síndromes mielodisplásicos.Quimioterapia 0.302945 linfocítica aguda 0.307126 siguientes procedimientos 0.33161 siguientes aspectos 0.303162 Neurofibromatosis tipo 0.303799 células madre formadoras 0.308269 siguientes especialistas 0.302945 hueso compacto 0.308024 neoplasias mieloides 0.310246 célula madre mieloide 0.324347 Bultos indoloros 0.302618 líquido cefalorraquídeo 0.326401 leucemia mielomonocítica 0.41887 Instituto Nacional 0.305639 célula madre linfoide 0.318549 siguientes problemas 0.302781 leucemia mielógena 0.419565 neoplasias mielodisplásicas 0.302899 LMA recién 0.316713 cáncer regrese).El 0.307025 madre mieloides 0.328575 células madre mieloides 0.318746 leucemia promielocítica aguda 0.371662 células madre 0.977959 leucemia mielógena aguda 0.321693	leucemia aguda 0.310888 leucemia linfoblástica aguda 0.335277 síndromes mielodisplásicos 0.43219 enlace drugs approved 0.308769 Acute Myeloid Leukemia 0.309058 infantil recidivante 0.30755 Sudores nocturnos 0.302372 efectos tardíos 0.309904 médula ósea.Leucemia mielógena 0.31318 células cancerosas.El gemtuzumab 0.309349 punción espinal.Ampliar 0.30255 leucemia granulocítica aguda 0.320187 PDQ Tratamiento 0.305949 blastocitos mieloides 0.303489 tirosina cinasa 0.339619 sistema nervioso central 0.381371 leucemia mieloblástica aguda 0.320188 Physician Data Query 0.305829 enfermedades mieloides 0.315553 SMD)Algunos tratamientos 0.302284 revés.La prueba 0.301997 leucemia mieloide aguda 0.981978 célula madre 0.354129 siguientes sumarios 0.305018	CLICK HERE
2070	National Cancer Institute	Html	es	Inhibidores de la angiogénesis	Hoja informativa que describe el proceso de eliminación de suministro de sangre a los tumores. Incluye una lista de los cánceres en los que se está probando este enfoque.	vasos sanguíneos resultantes 0.32417 NCI de estudios 0.304711 llamadas metástasis 0.305878 posibles efectos 0.304824 Drug Administration 0.306756	células renales 0.307581 angiogénesis efectos 0.326284 Estados Unidos 0.315596 vasos sanguíneos 0.986577	CLICK HERE
2115	National Cancer Institute	Html	es	Prevención del cáncer de hígado (hepatocelular) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer hepatocelular y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	chronic hepatitis b 0.391786 chronic hepatitis c 0.392121 available online 0.329517 American Cancer Society 0.362594 tt virus dna 0.321147 largo plazo 0.314356 with hepatocellular carcinoma 0.362577 hepatitis e 0.456465 CHC agudo 0.334135 denominación hepatitis no-A 0.402257 hepatocellular carcinoma 0.818192 Concurrent hepatitis 0.385001 Instituto Nacional 0.321684 Qidong hepatitis 0.385791 patients with chronic 0.340288 hígado llamada cirrosis 0.31992 hepatitis nanb 0.397414 risk factors 0.334046 hepatitis b 0.815878 hepatitis c 0.64216 Estados Unidos 0.516836 virus hepáticos forma 0.324783 Universal hepatitis 0.404867 Spanish patients with 0.316748 PDQ Prevención 0.319178	patients with 0.420437 carcinoma among patients 0.322468 SEER Cancer Statistics 0.314302 Rizzetto M 0.316034 Infect Dis 0.316615 virus carriers with 0.326772 natural history 0.314507 Ningún virus 0.321223 hepatocelular factores causales 0.320088 Viral Hepatitis FAQs 0.396943 National Cancer Institute 0.335176 La hepatitis 0.94804 Chang MH 0.316907 viral hepatitis 0.515061 Yuan JM 0.316452 GB virus 0.317604 correlate with expression 0.314623 Long-term phlebotomy with 0.314798 Liver Int 0.354023 Hepatocellular carcinoma without 0.326846 chronic hepatitis 0.450334 hepatitis aguda 0.53174 hepatitis tipos 0.394509 virus rna 0.317794	CLICK HERE
2974	National Cancer Institute	Video	en	Challenge: Fitting fitness into your busy schedule	Life can get really hectic sometimes. Between work, family and other obligations, it's hard to find time to exercise. But before you say you don't have time to exercise each day, consider this: even a little bit of exercise is better than no exercise at all!	little bit 0.820288 fitness 0.392435 work 0.370295 obligations 0.461065	Life 0.388039 exercise 0.667358 time 0.674488 family 0.369813	CLICK HERE
3570	National Cancer Institute	Html	en	The NCI Outstanding Investigator Award (R35)	The NCI Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to continue or embark on projects of unusual potential in cancer research.	direct costs 0.516422 projects 0.339999 person months effort 0.510514 OIA 0.56501 greater risks 0.517599 Institution 0.338577 outstanding productivity 0.586579 cancer research 0.764353 funded investigators 0.583615	Award 0.340824 NCI Outstanding Investigator 0.903247 outstanding records 0.61157 recipient 0.352813 Principal Investigator 0.547103 PI 0.388963 substantial time 0.526242 NCI grant 0.541618 salary support 0.509963	CLICK HERE
16680	National Cancer Institute	Html	en	Cancer Moonshot℠ Implementation	Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.	Cancer Moonshot-related research 0.688251 ongoing efforts 0.579887 funding opportunity announcements 0.69197 authorization 0.517804 oversight 0.515337 Cancer Moonshot portfolio 0.716496 academia 0.515431 Cancer Moonshot goals 0.684682 Century Cures Act 0.85793 expansions 0.51624 implementation teams 0.716347 email Partnerships_CancerMoonshot 0.582993 list 0.516345 Scientific Advisors 0.584259 important role 0.585193 longer-term scientific initiatives 0.700429 research opportunities 0.75591 multiple ways 0.591922 private sector 0.587499 Cancer Moonshot 0.987984 Cancer Moonshot initiatives 0.68956 concept proposals 0.656557 automatic email 0.583279 receipt 0.519207	NCI intramural staff 0.745934 cancer research community 0.682183 NCI extramural program 0.749793 Program Leadership Committee 0.655079 potential partners 0.586537 available FOAs 0.62206 NCI’s Board 0.674346 NIH institutes 0.582819 existing funds 0.59672 new research opportunities 0.683581 21st Century Cures 0.861565 scientific opportunities 0.594628 Blue Ribbon Panel 0.846596 BRP recommendation 0.740701 working groups 0.588634 new funding concepts 0.653803 BRP recommendations 0.654047 Public-private partnerships 0.590589 Cancer Moonshot implementation 0.678145 NCI advisory committees 0.753041 NCI’s Scientific 0.67691 report 0.517155 new programs 0.586358 funding mechanism 0.587953	CLICK HERE
16708	National Cancer Institute	Html	en	ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers	ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol	certain genetic alterations 0.511031 ALK gene rearrangement 0.86792 specific genetic alterations 0.510493 lung cancer 0.965003 ALK genetic alterations 0.561732 component trials 0.510228 National Clinical Trials 0.497396 clinical trials 0.62346 early-stage lung cancer 0.707269 EGFR gene mutation 0.628828 best treatment approach 0.483241 lung cancers 0.649896 ALK Treatment component 0.564764 ECOG-ACRIN Cancer Research 0.536673 ALK rearrangement 0.515701 non-small cell lung 0.519586 Adjuvant Lung Cancer 0.554841 EGFR gene mutations 0.510846 uncommon genetic changes 0.484048 ALCHEMIST treatment trial 0.613717 new treatment approaches 0.481108 lung carcinoid tumors 0.539366 early-stage lung cancers 0.57159 appropriate ALCHEMIST treatment 0.663904	ALK gene 0.888431 precision medicine trials 0.560161 tumor tissue 0.58358 United States 0.513049 Dana-Farber Cancer Institute 0.495276 ALK alterations 0.531283 small cell lung 0.519071 National Cancer Institute 0.484824 ALCHEMIST study 0.594796 cancer risk characteristics 0.487226 EGFR Treatment component 0.512344 participants 0.568322 ALCHEMIST treatment trials 0.868218 genetic alterations 0.637424 complete surgical removal 0.527484 Cancer Research Group 0.536403 early-stage lung adenocarcinoma 0.54246 cell lung cancer 0.575738 Cancer Genomics 0.482098 FDA-approved Vysis ALK 0.52631 ALCHEMIST screening trial 0.716569 ALCHEMIST trials 0.680442 standard therapy 0.505511 Clinical Trials Agreement 0.491455	CLICK HERE